- Home
- NAAS vs HCWB Comparison
NAAS vs HCWB Comparison
Compare NAAS & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAAS
- HCWB
- Stock Information
- Founded
- NAAS 2019
- HCWB 2018
- Country
- NAAS China
- HCWB United States
- Employees
- NAAS N/A
- HCWB N/A
- Industry
- NAAS Other Specialty Stores
- HCWB Biotechnology: Pharmaceutical Preparations
- Sector
- NAAS Consumer Discretionary
- HCWB Health Care
- Exchange
- NAAS Nasdaq
- HCWB Nasdaq
- Market Cap
- NAAS 9.0M
- HCWB 8.4M
- IPO Year
- NAAS 2017
- HCWB 2021
- Fundamental
- Price
- NAAS $3.50
- HCWB $3.89
- Analyst Decision
- NAAS
- HCWB Strong Buy
- Analyst Count
- NAAS 0
- HCWB 1
- Target Price
- NAAS N/A
- HCWB $35.00
- AVG Volume (30 Days)
- NAAS 59.0K
- HCWB 94.5K
- Earning Date
- NAAS 11-19-2025
- HCWB 11-13-2025
- Dividend Yield
- NAAS N/A
- HCWB N/A
- EPS Growth
- NAAS N/A
- HCWB N/A
- EPS
- NAAS N/A
- HCWB N/A
- Revenue
- NAAS $21,817,052.00
- HCWB $832,841.00
- Revenue This Year
- NAAS $378.49
- HCWB $178.64
- Revenue Next Year
- NAAS N/A
- HCWB N/A
- P/E Ratio
- NAAS N/A
- HCWB N/A
- Revenue Growth
- NAAS N/A
- HCWB N/A
- 52 Week Low
- NAAS $1.96
- HCWB $2.77
- 52 Week High
- NAAS $55.84
- HCWB $100.80
- Technical
- Relative Strength Index (RSI)
- NAAS 49.63
- HCWB 45.35
- Support Level
- NAAS $3.40
- HCWB $4.00
- Resistance Level
- NAAS $3.72
- HCWB $4.07
- Average True Range (ATR)
- NAAS 0.35
- HCWB 0.22
- MACD
- NAAS -0.04
- HCWB -0.02
- Stochastic Oscillator
- NAAS 44.78
- HCWB 4.76
About NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.